These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 26923095)

  • 1. Association between baseline serum glucose, triglycerides and total cholesterol, and prostate cancer risk categories.
    Arthur R; Møller H; Garmo H; Holmberg L; Stattin P; Malmstrom H; Lambe M; Hammar N; Walldius G; Robinson D; Jungner I; Hemelrijck MV
    Cancer Med; 2016 Jun; 5(6):1307-18. PubMed ID: 26923095
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum lipid levels and prostate cancer severity among Hispanic Puerto Rican men.
    Salgado-Montilla J; Soto Salgado M; Surillo Trautmann B; Sánchez-Ortiz R; Irizarry-Ramírez M
    Lipids Health Dis; 2015 Sep; 14():111. PubMed ID: 26377420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum inflammatory markers in relation to prostate cancer severity and death in the Swedish AMORIS study.
    Arthur R; Williams R; Garmo H; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinsson D; Jungner I; Van Hemelrijck M
    Int J Cancer; 2018 Jun; 142(11):2254-2262. PubMed ID: 29322512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study.
    Arthur R; Møller H; Garmo H; Häggström C; Holmberg L; Stattin P; Malmström H; Lambe M; Hammar N; Walldius G; Robinson D; Jungner I; Van Hemelrijck M
    Cancer Causes Control; 2019 Feb; 30(2):195-206. PubMed ID: 30421156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer.
    Murtola TJ; Kasurinen TVJ; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):66-76. PubMed ID: 30214034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose, lipids and gamma-glutamyl transferase measured before prostate cancer diagnosis and secondly diagnosed primary tumours: a prospective study in the Swedish AMORIS cohort.
    Bosco C; Garmo H; Hammar N; Walldius G; Jungner I; Malmström H; Holmberg L; Van Hemelrijck M
    BMC Cancer; 2018 Feb; 18(1):205. PubMed ID: 29463235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
    Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
    Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood cholesterol, tumor clinical characteristics and risk of prostate cancer progression after radical prostatectomy.
    Rantaniemi L; Tammela TLJ; Kujala P; Murtola TJ
    Scand J Urol; 2018 Aug; 52(4):269-276. PubMed ID: 30362865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low levels of apolipoprotein A-I and HDL are associated with risk of prostate cancer in the Swedish AMORIS study.
    Van Hemelrijck M; Walldius G; Jungner I; Hammar N; Garmo H; Binda E; Hayday A; Lambe M; Holmberg L
    Cancer Causes Control; 2011 Jul; 22(7):1011-9. PubMed ID: 21562751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: results from a multicentre prospective study.
    De Nunzio C; Simone G; Brassetti A; Mastroianni R; Collura D; Muto G; Gallucci M; Tubaro A
    BMC Cancer; 2016 Jul; 16():407. PubMed ID: 27386844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer risk in the Swedish AMORIS study: the interplay among triglycerides, total cholesterol, and glucose.
    Van Hemelrijck M; Garmo H; Holmberg L; Walldius G; Jungner I; Hammar N; Lambe M
    Cancer; 2011 May; 117(10):2086-95. PubMed ID: 21523720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.
    Jamnagerwalla J; Howard LE; Allott EH; Vidal AC; Moreira DM; Castro-Santamaria R; Andriole GL; Freeman MR; Freedland SJ
    Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):252-259. PubMed ID: 29282360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose and lipoprotein biomarkers and breast cancer severity using data from the Swedish AMORIS cohort.
    Melvin JC; Garmo H; Holmberg L; Hammar N; Walldius G; Jungner I; Lambe M; Van Hemelrijck M
    BMC Cancer; 2017 Apr; 17(1):246. PubMed ID: 28376727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer.
    Murtola TJ; Sälli SM; Talala K; Taari K; Tammela TLJ; Auvinen A
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):453-460. PubMed ID: 30679762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
    Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High Lipoprotein(a) Level Is Independently Associated with Adverse Clinicopathological Features in Patients with Prostate Cancer.
    Wang FM; Zhang Y
    Dis Markers; 2019; 2019():9483935. PubMed ID: 31885745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
    Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
    Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
    Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
    Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.